Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CorMedix (CRMD) Depreciation & Amortization (CF) (2016 - 2025)

CorMedix's Depreciation & Amortization (CF) history spans 13 years, with the latest figure at $294096.0 for Q4 2025.

  • For Q4 2025, Depreciation & Amortization (CF) rose 259.57% year-over-year to $294096.0; the TTM value through Dec 2025 reached $677000.0, up 339.61%, while the annual FY2025 figure was $677000.0, 339.61% up from the prior year.
  • Depreciation & Amortization (CF) for Q4 2025 was $294096.0 at CorMedix, up from $161917.0 in the prior quarter.
  • Across five years, Depreciation & Amortization (CF) topped out at $294096.0 in Q4 2025 and bottomed at $11994.0 in Q1 2021.
  • The 5-year median for Depreciation & Amortization (CF) is $21826.0 (2024), against an average of $58492.4.
  • The largest annual shift saw Depreciation & Amortization (CF) crashed 75.15% in 2021 before it surged 535.97% in 2025.
  • A 5-year view of Depreciation & Amortization (CF) shows it stood at $20047.0 in 2021, then increased by 12.32% to $22516.0 in 2022, then dropped by 25.11% to $16863.0 in 2023, then surged by 385.03% to $81790.0 in 2024, then soared by 259.57% to $294096.0 in 2025.
  • Per Business Quant, the three most recent readings for CRMD's Depreciation & Amortization (CF) are $294096.0 (Q4 2025), $161917.0 (Q3 2025), and $110993.0 (Q2 2025).